| 2.57 0.07 (2.8%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.49  |
1-year : | 4.06 |
| Resists | First : | 2.99 |
Second : | 3.48 |
| Pivot price | 2.51 |
|||
| Supports | First : | 2.2 | Second : | 1.83 |
| MAs | MA(5) : | 2.54  |
MA(20) : | 2.64 |
| MA(100) : | 3.16 |
MA(250) : | 2.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.3 |
D(3) : | 39.9 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 3.84 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NSPR ] has closed below upper band by 41.4%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.74 - 2.75 | 2.75 - 2.77 |
| Low: | 2.48 - 2.49 | 2.49 - 2.51 |
| Close: | 2.55 - 2.57 | 2.57 - 2.59 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Fri, 08 Dec 2023
Is InspireMD Inc (NSPR) Stock a Good Value Friday? - InvestorsObserver
Wed, 06 Dec 2023
Gary Roubin Spends US$127k Buying InspireMD Shares - Simply Wall St
Wed, 06 Dec 2023
InspireMD's Gary Roubin Acquires 13% More Stock - Yahoo Finance
Tue, 05 Dec 2023
Should You Sell InspireMD Inc (NSPR) in Medical Devices Industry? - InvestorsObserver
Mon, 04 Dec 2023
InspireMD says Roubin buys 50K shares in co (NASDAQ:NSPR) - Seeking Alpha
Tue, 07 Nov 2023
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 88 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | -362.4 % |
| Return on Assets (ttm) | -32.5 % |
| Return on Equity (ttm) | -59.5 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -2 |
| PEG Ratio | 0 |
| Price to Book value | 1.27 |
| Price to Sales | 10.12 |
| Price to Cash Flow | -3.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|